Sisram Deepens China Roots with New Hub to Tap Aesthetics Boom

HONG KONG – January 21, 2026 – Global wellness group Sisram Medical Ltd has announced a significant strategic move to solidify its presence in Asia, entering into a memorandum of understanding to establish a next-generation manufacturing and innovation hub in China. The partnership, forged between its subsidiary Sisram Medical China and Sinmait Medical Technology, a subsidiary of its majority owner Shanghai Fosun Pharmaceutical, marks a major acceleration of the company's localization strategy in one of the world's fastest-growing medical aesthetics markets.

The new hub will initially focus on the localized production of Sisram's core Energy-Based Devices (EBD) and is designed to evolve into a comprehensive center for a broader portfolio. This initiative aims not only to cater to surging domestic demand but also to serve as a strategic base for the entire APAC region, enhancing supply chain resilience and fostering localized research and development.

A Strategic Pivot: 'In China, For Global'

This collaboration is a cornerstone of Sisram's 'In China, for Global' vision, a strategy designed to build a deeply integrated and competitive local presence that can also support worldwide operations. By leveraging the manufacturing prowess and local expertise of Sinmait, Sisram intends to create a more agile and robust supply chain, reducing its dependence on external factors and geopolitical disruptions that have challenged global industries in recent years.

"This collaboration with Fosun Pharma elevates Sisram's localization strategy in China to a new level," said Mr. Lior Dayan, Chairman and Executive Director of Sisram Medical, in a statement. "The core significance of this partnership lies in building a comprehensive, resilient, and competitive localized ecosystem. It represents a key milestone in our vision of 'In China, for Global,' setting the foundation for scalable, sustainable growth and long-term value creation."

The new facility is poised to become a critical node in Sisram's global network, responsible for scalable production, advanced logistics, and cutting-edge R&D. This dual-purpose approach—serving the local Chinese market while simultaneously bolstering its capacity for the wider APAC region—positions the company to capitalize on regional growth trends more effectively.

Navigating China's Med-Tech Gold Rush

Sisram's deepened investment comes as China's medical aesthetics market experiences explosive growth. In 2023, the market's revenue soared to 200 billion yuan (approximately $27.6 billion), a 20% increase from the previous year. Projections indicate this momentum will continue, with a compound annual growth rate (CAGR) widely expected to hover around 15% for the next several years. This expansion is fueled by rising disposable incomes, a burgeoning middle class projected to exceed 550 million by 2025, and a cultural shift that has normalized non-surgical cosmetic procedures.

Despite this rapid expansion, the market remains far from saturated. China's medical aesthetics penetration rate stood at just 4.5% in 2022, lagging significantly behind more mature markets like South Korea, the United States, and Japan. This gap signals a vast, untapped consumer base and a long runway for growth, a potential that global firms like Sisram are keen to unlock. The demand is particularly strong for non-invasive treatments like those offered by Sisram's EBDs, which promise effective results with minimal downtime.

The Localization Imperative

Beyond market opportunity, Sisram's move is a calculated response to China's evolving economic and regulatory landscape. The Chinese government has made domestic production a national priority through ambitious initiatives like "Made in China 2025" and "Healthy China 2030." These policies aim to significantly increase the use of domestically produced medical devices in the nation's top hospitals and are reinforced by procurement practices like Volume-Based Procurement (VBP) that heavily favor local manufacturers.

For foreign companies, this creates a powerful incentive—and often a strategic necessity—to localize operations. Establishing a domestic manufacturing footprint allows companies to navigate "buy-local" mandates, benefit from favorable policies, and compete on a more level playing field with ascendant domestic brands. Sisram is not alone in this realization; other multinational giants in the med-tech space, including Danaher and Siemens Healthineers, have also announced substantial investments in local R&D and manufacturing bases to secure their long-term future in China. This trend underscores a broader shift where simply importing products is no longer a viable long-term strategy for market leadership.

The Fosun Ecosystem Advantage

The partnership is more than a standard joint venture; it represents a strategic alignment within the formidable Fosun Pharma ecosystem. As the majority owner of Sisram since its 2017 Hong Kong IPO, Fosun Pharma provides a unique advantage. By partnering with Sinmait, another Fosun subsidiary, Sisram is tapping into a trusted network with established infrastructure and deep-seated knowledge of the local regulatory and business environment. This internal synergy is expected to streamline the establishment of the new hub and de-risk the expansion process.

This deep integration allows Sisram to leverage what the company calls Sinmait's "advanced production capabilities and local expertise" to its fullest extent. It transforms Sisram from a foreign entity operating in China into a deeply embedded player with local roots, creating a powerful competitive moat. This structure is designed to consolidate Fosun's and Sisram's collective influence over the Chinese and APAC medical aesthetics market, creating a vertically integrated powerhouse from R&D and manufacturing to sales and service.

Reshaping Wellness for Chinese Consumers

Ultimately, the strategic maneuvers are aimed at delivering tangible benefits to the end consumer. With the rising popularity of combined therapies—where EBD treatments are used in conjunction with products like injectables—localized production and R&D become critical. A domestic innovation hub will enable Sisram to develop and refine synergistic treatments tailored specifically to the needs and preferences of Chinese patients.

The press release noted that this localized development will "significantly enhance the portfolio's overall effectiveness." By manufacturing EBDs in China, Sisram can improve accessibility, reduce costs, and shorten delivery times, making its award-winning technologies available to a wider segment of the population. This move promises to provide Chinese consumers with a greater array of high-quality, domestically produced wellness solutions, further fueling innovation and competition within the country's dynamic health and beauty sector.